novo nordisk a/s - somapacitan - růst - hypofýzy a hypotalamické hormony a analogy - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).
Evropská unie -
čeština -
EMA (European Medicines Agency)